

# Marie Essig

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3367868/publications.pdf>

Version: 2024-02-01

132  
papers

6,852  
citations

81743

39  
h-index

82410

72  
g-index

152  
all docs

152  
docs citations

152  
times ranked

8527  
citing authors

#	ARTICLE	IF	CITATIONS
1	Estimating Extracellular Fluid Volume in Healthy Individuals: Evaluation of Existing Formulae and Development of a New Equation. <i>Kidney International Reports</i> , 2022, 7, 810-822.	0.4	1
2	The Case   Hypereosinophilia in a hemodialysis patient. <i>Kidney International</i> , 2022, 101, 657-658.	2.6	1
3	Higher mortality risk among kidney transplant recipients than among estimated glomerular filtration rate-matched patients with CKD preliminary results. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 176-184.	0.4	4
4	Less arterial stiffness in kidney transplant recipients than chronic kidney disease patients matched for renal function. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 1244-1254.	1.4	6
5	Sofosbuvir and the risk of kidney dysfunction. <i>Journal of Hepatology</i> , 2021, 74, 256-257.	1.8	1
6	Renal involvement in eosinophilic granulomatosis with polyangiitis (EGPA): a multicentric retrospective study of 63 biopsy-proven cases. <i>Rheumatology</i> , 2021, 60, 359-365.	0.9	27
7	The spectrum of kidney biopsies in hospitalized patients with COVID-19, acute kidney injury and/or proteinuria. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 1253-1262.	0.4	54
8	Urgent-start dialysis in patients referred early to a nephrologist the CKD-REIN prospective cohort study. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 1500-1510.	0.4	4
9	Effect of Sevelamer and Nicotinamide on Albumin Carbamylation in Patients with End-Stage Kidney Disease. <i>Drugs in R and D</i> , 2021, 21, 231-238.	1.1	3
10	High Mortality and Graft Loss after Infective Endocarditis in Kidney Transplant Recipients: A Case-Controlled Study from Two Centers. <i>Pathogens</i> , 2021, 10, 1023.	1.2	5
11	Heterogeneous neutralizing antibodies production after Sars-Cov2 vaccination in hemodialysis patients. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 2616-2617.	1.4	0
12	Evaluation of Longitudinal Exposure to Tacrolimus as a Risk Factor of Chronic Kidney Disease Occurrence Within the First-year Post-Liver Transplantation. <i>Transplantation</i> , 2021, 105, 1585-1594.	0.5	4
13	Adherence profiles in kidney transplant patients: Causes and consequences. <i>Patient Education and Counseling</i> , 2020, 103, 189-198.	1.0	34
14	Prevalence of atheromatous and non-atheromatous cardiovascular disease by age in chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 827-836.	0.4	23
15	Urinary Protein Biomarker Panel for the Diagnosis of Antibody-Mediated Rejection in Kidney Transplant Recipients. <i>Kidney International Reports</i> , 2020, 5, 1448-1458.	0.4	26
16	Viral metagenomics analysis of kidney donors and recipients: Torque teno virus genotyping and prevalence. <i>Journal of Medical Virology</i> , 2020, 92, 3301-3311.	2.5	16
17	Urinary Sodium-to-Potassium Ratio and Blood Pressure in CKD. <i>Kidney International Reports</i> , 2020, 5, 1240-1250.	0.4	9
18	The COVID-19 outbreak and the angiotensin-converting enzyme 2: too little or too much?. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1073-1075.	0.4	5

#	ARTICLE	IF	CITATIONS
19	Population pharmacokinetics of gentamicin in haemodialysis patients: modelling, simulations and recommendations. <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 947-955.	0.8	3
20	Indirect effects of severe acute respiratory syndrome coronavirus 2 on the kidney in coronavirus disease patients. <i>CKJ: Clinical Kidney Journal</i> , 2020, 13, 347-353.	1.4	34
21	Severe Infection in Anti-Glomerular Basement Membrane Disease: A Retrospective Multicenter French Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 698.	1.0	5
22	Transcriptional Changes in Kidney Allografts with Histology of Antibody-Mediated Rejection without Anti-HLA Donor-Specific Antibodies. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 2168-2183.	3.0	60
23	Antibody-mediated rejection with and without donor-specific anti-human leucocyte antigen antibodies: performance of the peripheral blood 8-gene expression assay. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1328-1337.	0.4	6
24	First-in-human use of a marine oxygen carrier (M101) for organ preservation: A safety and proof-of-principle study. <i>American Journal of Transplantation</i> , 2020, 20, 1729-1738.	2.6	44
25	Isofosfamide nephrotoxicity in adult patients. <i>CKJ: Clinical Kidney Journal</i> , 2020, 13, 660-665.	1.4	26
26	Development and validation of an optimized integrative model using urinary chemokines for noninvasive diagnosis of acute allograft rejection. <i>American Journal of Transplantation</i> , 2020, 20, 3462-3476.	2.6	38
27	The Fc $\gamma$ RIIIA $\Delta$ 158 VV genotype increased the risk of post-transplant lymphoproliferative disorder in T $\alpha$ cell-depleted kidney transplant recipients – a retrospective study. <i>Transplant International</i> , 2020, 33, 936-947.	0.8	3
28	Severe acute respiratory syndrome coronavirus 2 indirectly damages kidney structures. <i>CKJ: Clinical Kidney Journal</i> , 2020, 13, 1101-1104.	1.4	6
29	Subclinical proximal tubulopathy in hepatitis B: The roles of nucleot(s)ide analogue treatment and the hepatitis B virus. <i>World Journal of Hepatology</i> , 2020, 12, 1326-1340.	0.8	2
30	Cyclosporine A inhibits MRTF $\alpha$ -SRF signaling through Na <sup>+</sup> /K <sup>+</sup> ATPase inhibition and actin remodeling. <i>FASEB BioAdvances</i> , 2019, 1, 561-578.	1.3	1
31	Achievement of Low-Density Lipoprotein Cholesterol Targets in CKD. <i>Kidney International Reports</i> , 2019, 4, 1546-1554.	0.4	15
32	Development and validation of a peripheral blood mRNA assay for the assessment of antibody-mediated kidney allograft rejection: A multicentre, prospective study. <i>EBioMedicine</i> , 2019, 46, 463-472.	2.7	75
33	Sum of peak intensities outperforms peak area integration in iTRAQ protein expression measurement by LC-MS/MS using a TripleTOF 5600+ platform. <i>Bioscience Reports</i> , 2019, 39, .	1.1	7
34	A Prognostic Tool for Individualized Prediction of Graft Failure Risk within Ten Years after Kidney Transplantation. <i>Journal of Transplantation</i> , 2019, 2019, 1-10.	0.3	6
35	Adverse events associated with currently used medical treatments for cystinuria and treatment goals: results from a series of 442 patients in France. <i>BJU International</i> , 2019, 124, 849-861.	1.3	30
36	Pharmacokinetics of Prolonged-Release Once-Daily Formulations of Tacrolimus in De Novo Kidney Transplant Recipients: A Randomized, Parallel-Group, Open-Label, Multicenter Study. <i>Advances in Therapy</i> , 2019, 36, 462-477.	1.3	25

#	ARTICLE	IF	CITATIONS
37	Natural killer cell infiltration is discriminative for antibody-mediated rejection and predicts outcome after kidney transplantation. <i>Kidney International</i> , 2019, 95, 188-198.	2.6	116
38	Pharmacokinetic Therapeutic Drug Monitoring of Advagraf in More Than 500 Adult Renal Transplant Patients, Using an Expert System Online. <i>Therapeutic Drug Monitoring</i> , 2018, 40, 285-291.	1.0	23
39	Predictive factors of spontaneous CMV DNAemia clearance in kidney transplantation. <i>Journal of Clinical Virology</i> , 2018, 99-100, 38-43.	1.6	4
40	Structural patterns of the human ABCC4/MRP4 exporter in lipid bilayers rationalize clinically observed polymorphisms. <i>Pharmacological Research</i> , 2018, 133, 318-327.	3.1	19
41	Recurrence of Renal Cell Cancer After Renal Transplantation in a Multicenter French Cohort. <i>Transplantation</i> , 2018, 102, 860-867.	0.5	18
42	An open-label randomized controlled trial of low-dose corticosteroid plus enteric-coated mycophenolate sodium versus standard corticosteroid treatment for minimal change nephrotic syndrome in adults (MSN Study). <i>Kidney International</i> , 2018, 94, 1217-1226.	2.6	20
43	Beyond serum creatinine: which tools to evaluate renal function in cirrhotic patients?. <i>Hepatology Research</i> , 2018, 48, 771-779.	1.8	9
44	Evaluation of the adequacy of drug prescriptions in patients with chronic kidney disease: results from the CKDâ€REIN cohort. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 2811-2823.	1.1	64
45	Development of a standardized real time PCR for Torque teno viruses (TTV) viral load detection and quantification: A new tool for immune monitoring. <i>Journal of Clinical Virology</i> , 2018, 105, 118-127.	1.6	40
46	Genome-Wide Association Study of Acute Renal Graft Rejection. <i>American Journal of Transplantation</i> , 2017, 17, 201-209.	2.6	50
47	Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 348-358.	3.0	286
48	Outcome and Treatment of Nocardiosis After Solid Organ Transplantation: New Insights From a European Study. <i>Clinical Infectious Diseases</i> , 2017, 64, 1396-1405.	2.9	91
49	Evaluation of Experiences with Immunosuppressive Drugs in Transplantation: Validation of the MESI Scale in French. <i>Pharmaceutical Medicine</i> , 2017, 31, 455-465.	1.0	2
50	Reduction of Extended-Release Tacrolimus Dose in Low-Immunological-Risk Kidney Transplant Recipients Increases Risk of Rejection and Appearance of Donor-Specific Antibodies: A Randomized Study. <i>American Journal of Transplantation</i> , 2017, 17, 1370-1379.	2.6	85
51	An adjustable predictive score of graft survival in kidney transplant patients and the levels of risk linked to de novo donor-specific anti-HLA antibodies. <i>PLoS ONE</i> , 2017, 12, e0180236.	1.1	15
52	Anti-hepatitis C virus drugs and kidney. <i>World Journal of Hepatology</i> , 2016, 8, 1343.	0.8	16
53	Evolution and Determinants of Health-Related Quality-of-Life in Kidney Transplant Patients Over the First 3 Years After Transplantation. <i>Transplantation</i> , 2016, 100, 640-647.	0.5	29
54	Establishing Biomarkers in Transplant Medicine. <i>Transplantation</i> , 2016, 100, 2024-2038.	0.5	71

#	ARTICLE	IF	CITATIONS
55	<i>Nocardia</i> Infection in Solid Organ Transplant Recipients: A Multicenter European Case-control Study. <i>Clinical Infectious Diseases</i> , 2016, 63, 338-345.	2.9	179
56	Contribution of next generation sequencing to early detection of cytomegalovirus UL97 emerging mutants and viral subpopulations analysis in kidney transplant recipients. <i>Journal of Clinical Virology</i> , 2016, 80, 74-81.	1.6	26
57	Uterus human leucocyte antigen expression in the perspective of transplantation. <i>Journal of Obstetrics and Gynaecology Research</i> , 2016, 42, 1789-1795.	0.6	2
58	Multidrug resistance-associated protein 4 (MRP4) controls ganciclovir intracellular accumulation and contributes to ganciclovir-induced neutropenia in renal transplant patients. <i>Pharmacological Research</i> , 2016, 111, 501-508.	3.1	19
59	Minimization of maintenance immunosuppressive therapy after renal transplantation comparing cyclosporine A/azathioprine or cyclosporine A/mycophenolate mofetil bitherapy to cyclosporine A monotherapy: a 10-year postrandomization follow-up study. <i>Transplant International</i> , 2016, 29, 23-33.	0.8	12
60	Uterus transplantation in France: for which patients?. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2016, 205, 7-10.	0.5	24
61	Plasma and intracellular exposure to ganciclovir in adult renal transplant recipients: is there an association with haematological toxicity?. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 484-489.	1.3	25
62	A candidate gene approach of the calcineurin pathway to identify variants associated with clinical outcomes in renal transplantation. <i>Pharmacogenomics</i> , 2016, 17, 375-391.	0.6	13
63	Bronchiectasis diagnosed after renal transplantation: a retrospective multicenter study. <i>BMC Pulmonary Medicine</i> , 2015, 15, 141.	0.8	8
64	Development of a new real time PCR quantitative assay for the detection of Torque teno virus (TTV): A new tool for immunomonitoring?. <i>Journal of Clinical Virology</i> , 2015, 70, S93.	1.6	0
65	<sc>HCV</sc>â€œassociated <sc>B</sc>â€œcell nonâ€œ<sc>H</sc>odgkin lymphomas and new direct antiviral agents. <i>Liver International</i> , 2015, 35, 2222-2227.	1.9	58
66	Indomethacin, Amiloride, or Eplerenone for Treating Hypokalemia in Gitelman Syndrome. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 468-475.	3.0	69
67	Drug-Induced Nephrotoxicity: A Frequent Cause of Hospitalization In Nephrology. <i>Clinical Therapeutics</i> , 2015, 37, e28.	1.1	0
68	Liquid chromatography tandem mass spectrometry quantitation of intracellular concentrations of ganciclovir and its phosphorylated forms. <i>Analytical and Bioanalytical Chemistry</i> , 2015, 407, 3449-3456.	1.9	10
69	CKD and Its Risk Factors among Patients with Cystinuria. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 842-851.	2.2	71
70	Clinical characteristics and outcomes of childhood-onset ANCA-associated vasculitis: a French nationwide study. <i>Nephrology Dialysis Transplantation</i> , 2015, 30 Suppl 1, i104-12.	0.4	45
71	How to handle missed or delayed doses of tacrolimus in renal transplant recipients? A pharmacokinetic investigation. <i>Pharmacological Research</i> , 2015, 100, 281-287.	3.1	18
72	<sc>eGFR</sc> decrease during antiviral C therapy with first generation protease inhibitors: a clinical significance?. <i>Liver International</i> , 2015, 35, 71-78.	1.9	18

#	ARTICLE	IF	CITATIONS
73	Light chain deposition disease without glomerular proteinuria: a diagnostic challenge for the nephrologist. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1894-1902.	0.4	29
74	UMOD polymorphism rs12917707 is not associated with severe or stable IgA nephropathy in a large Caucasian cohort. <i>BMC Nephrology</i> , 2014, 15, 138.	0.8	2
75	P1098 DOES THE INITIAL AND REVERSIBLE DECREASE OF EGFR DURING TRIPLE THERAPY WITH TELAPREVIR REVEAL A REAL RENAL TOXICITY?. <i>Journal of Hepatology</i> , 2014, 60, S444.	1.8	0
76	Severe renal impairment during triple therapy with telaprevir. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2014, 38, e69-e71.	0.7	5
77	CKD GENERAL AND CLINICAL EPIDEMIOLOGY 1. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, iii124-iii139.	0.4	1
78	Renal impairment is frequent in chronic hepatitis C patients under triple therapy with telaprevir or boceprevir. <i>Hepatology</i> , 2014, 59, 2426-2426.	3.6	9
79	Calcineurin Activity Assay Measurement by Liquid Chromatography-Tandem Mass Spectrometry in the Multiple Reaction Monitoring Mode. <i>Clinical Chemistry</i> , 2014, 60, 353-360.	1.5	14
80	Exposure to Mycophenolic Acid Better Predicts Immunosuppressive Efficacy Than Exposure to Calcineurin Inhibitors in Renal Transplant Patients. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 96, 508-515.	2.3	34
81	The clinical status and survival in elderly dialysis: example of the oldest region of France. <i>BMC Nephrology</i> , 2013, 14, 131.	0.8	19
82	751 IS HBV-RELATED RENAL TUBULOPATHY BEFORE ANY ANTIVIRAL TREATMENT A REALITY?. <i>Journal of Hepatology</i> , 2013, 58, S304-S305.	1.8	0
83	Maribavir Use in Practice for Cytomegalovirus Infection in French Transplantation Centers. <i>Transplantation Proceedings</i> , 2013, 45, 1603-1607.	0.3	43
84	Impact of longitudinal exposure to mycophenolic acid on acute rejection in renal-transplant recipients using a joint modeling approach. <i>Pharmacological Research</i> , 2013, 72, 52-60.	3.1	26
85	Infective Endocarditis with Symptomatic Cerebral Complications: Contribution of Cerebral Magnetic Resonance Imaging. <i>Cerebrovascular Diseases</i> , 2013, 35, 327-336.	0.8	72
86	Serum and Lymphocytic Neurotrophins Profiles in Systemic Lupus Erythematosus: a Case-Control Study. <i>PLoS ONE</i> , 2013, 8, e79414.	1.1	12
87	Effect of Alendronate on HIV-Associated Osteoporosis: A Randomized, Double-Blind, Placebo-Controlled, 96-Week Trial (ANRS 120). <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 972-980.	0.5	36
88	Genome-Wide Association Study Identifies 13 loci Associated with Acute T-Cell Rejection in Caucasian Renal Transplant Patients. <i>Transplantation</i> , 2012, 94, 325.	0.5	0
89	MBV Use in Practice for Cytomegalovirus (CMV) Infection at Six French Transplant Centres. <i>Transplantation</i> , 2012, 94, 580.	0.5	0
90	<i>Bordetella holmesii</i> bacteremia in a renal transplant recipient: emergence of a new pathogen. <i>Transplant Infectious Disease</i> , 2012, 14, E134-6.	0.7	7

#	ARTICLE	IF	CITATIONS
91	Respective effects of early cerebral and abdominal magnetic resonance imaging on clinical decisions in infective endocarditis. <i>European Heart Journal Cardiovascular Imaging</i> , 2012, 13, 703-710.	0.5	49
92	Mapping cyclosporine-induced changes in protein secretion by renal cells using stable isotope labeling with amino acids in cell culture (SILAC). <i>Journal of Proteomics</i> , 2012, 75, 3674-3687.	1.2	14
93	Epidemiology of Posttransplant Lymphoproliferative Disorders in Adult Kidney and Kidney Pancreas Recipients: Report of the French Registry and Analysis of Subgroups of Lymphomas. <i>American Journal of Transplantation</i> , 2012, 12, 682-693.	2.6	166
94	Calcineurin regulation of cytoskeleton organization: a new paradigm to analyse the effects of calcineurin inhibitors on the kidney. <i>Journal of Cellular and Molecular Medicine</i> , 2012, 16, 218-227.	1.6	23
95	Factors Associated With Chronic Hepatitis in Patients With Hepatitis E Virus Infection Who Have Received Solid Organ Transplants. <i>Gastroenterology</i> , 2011, 140, 1481-1489.	0.6	570
96	Quantitative proteomic analysis of cyclosporine-induced toxicity in a human kidney cell line and comparison with tacrolimus. <i>Journal of Proteomics</i> , 2011, 75, 677-694.	1.2	36
97	129 PREDICTIVE FACTORS, NATURAL HISTORY AND OUTCOME OF CHRONIC HEPATITIS E VIRUS INFECTION IN SOLID-ORGAN-TRANSPLANT PATIENTS: A RETROSPECTIVE MULTICENTER STUDY. <i>Journal of Hepatology</i> , 2011, 54, S57.	1.8	1
98	Toward Understanding Renal Fanconi Syndrome: Step by Step Advances through Experimental Models. <i>Contributions To Nephrology</i> , 2011, 169, 247-261.	1.1	49
99	Uterine allotransplantation in ewes using an aortocava patch. <i>Human Reproduction</i> , 2011, 26, 3028-3036.	0.4	39
100	Effect of Early Cerebral Magnetic Resonance Imaging on Clinical Decisions in Infective Endocarditis. <i>Annals of Internal Medicine</i> , 2010, 152, 497.	2.0	228
101	Risk of diarrhoea in a long-term cohort of renal transplant patients given mycophenolate mofetil: the significant role of the <i>UGT1A8*2</i> variant allele. <i>British Journal of Clinical Pharmacology</i> , 2010, 69, 675-683.	1.1	40
102	Traditional Anthropometric Parameters Still Predict Metabolic Disorders in Women With Severe Obesity. <i>Obesity</i> , 2010, 18, 1026-1032.	1.5	41
103	Donor P-gp Polymorphisms Strongly Influence Renal Function and Graft Loss in a Cohort of Renal Transplant Recipients on Cyclosporine Therapy in a Long-Term Follow-Up. <i>Clinical Pharmacology and Therapeutics</i> , 2010, 88, 95-100.	2.3	66
104	Severe sirolimus-induced acute hepatitis in a renal transplant recipient. <i>Transplant International</i> , 2010, 23, no-no.	0.8	18
105	Drug-resistant cytomegalovirus in transplant recipients: a French cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 2628-2640.	1.3	141
106	Pregnancy-Associated Hemolytic Uremic Syndrome Revisited in the Era of Complement Gene Mutations. <i>Journal of the American Society of Nephrology: JASN</i> , 2010, 21, 859-867.	3.0	383
107	Addition of cyclophosphamide to steroids provides no benefit compared with steroids alone in treating adult patients with severe Henoch Schnlein Purpura. <i>Kidney International</i> , 2010, 78, 495-502.	2.6	128
108	Cerebral Microbleeds Are Frequent in Infective Endocarditis. <i>Stroke</i> , 2009, 40, 3461-3465.	1.0	97

#	ARTICLE	IF	CITATIONS
109	A renal transplant recipient with intraglomerular <i>Candida albicans</i> . <i>CKJ: Clinical Kidney Journal</i> , 2009, 2, 329-330.	1.4	0
110	Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients. <i>Aids</i> , 2009, 23, 817-824.	1.0	212
111	Hypophosphataemia: an easy strategy for diagnosis and treatment in HIV patients. <i>Antiviral Therapy</i> , 2009, 14, 481-8.	0.6	3
112	Hypophosphataemia: An Easy Strategy for Diagnosis and Treatment in HIV Patients. <i>Antiviral Therapy</i> , 2009, 14, 481-488.	0.6	11
113	Inhibitory ITAM Signaling by Fc $\gamma$ RI-Fc $\gamma$ RI <sup>3</sup> Chain Controls Multiple Activating Responses and Prevents Renal Inflammation. <i>Journal of Immunology</i> , 2008, 180, 2669-2678.	0.4	80
114	Initial therapy with nucleoside reverse transcriptase inhibitor-containing regimens is more effective than with regimens that spare them with no difference in short-term fat distribution: Hippocampe-ANRS 121 Trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 797-808.	1.3	23
115	An unusual pulmonary complication of cytomegalovirus infection in a renal transplant recipient. <i>CKJ: Clinical Kidney Journal</i> , 2008, 1, 236-238.	1.4	2
116	Is Phosphatemia the Best Tool to Monitor Renal Tenofovir Toxicity?. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007, 46, 256-258.	0.9	16
117	Cardiovascular remodelling and extracellular fluid excess in early stages of chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2007, 23, 239-248.	0.4	93
118	Fc $\gamma$ receptor I activation induces leukocyte recruitment and promotes aggravation of glomerulonephritis through the Fc $\gamma$ RI <sup>3</sup> adaptor. <i>European Journal of Immunology</i> , 2007, 37, 1116-1128.	1.6	48
119	Mast cells and inflammatory kidney disease. <i>Immunological Reviews</i> , 2007, 217, 79-95.	2.8	62
120	Exploring the role of galectin 3 in kidney function: a genetic approach. <i>Glycobiology</i> , 2006, 16, 36-45.	1.3	40
121	Mast Cell-Mediated Remodeling and Fibrinolytic Activity Protect against Fatal Glomerulonephritis. <i>Journal of Immunology</i> , 2006, 176, 5607-5615.	0.4	62
122	Tubular Shear Stress and Phenotype of Renal Proximal Tubular Cells. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, S33-S35.	3.0	42
123	Shear-stress-responsive signal transduction mechanisms in renal proximal tubule cells. <i>Current Opinion in Nephrology and Hypertension</i> , 2003, 12, 31-34.	1.0	15
124	Lovastatin Enhances Ecto-5'-Nucleotidase Activity and Cell Surface Expression in Endothelial Cells. <i>Circulation Research</i> , 2002, 90, 420-427.	2.0	55
125	Mechanical strains induced by tubular flow affect the phenotype of proximal tubular cells. <i>American Journal of Physiology - Renal Physiology</i> , 2001, 281, F751-F762.	1.3	91
126	Hypoparathyroidism. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2000, 67, 91-94.	0.0	2



#	ARTICLE	IF	CITATIONS
127	Effect of lipid-lowering strategies on tubular cell biology. <i>Kidney International</i> , 1999, 56, S92-S96.	2.6	8
128	3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Increase Fibrinolytic Activity in Rat Aortic Endothelial Cells. <i>Circulation Research</i> , 1998, 83, 683-690.	2.0	313
129	Dipyridamole decreases renal phosphate leak and augments serum phosphorus in patients with low renal phosphate threshold.. <i>Journal of the American Society of Nephrology: JASN</i> , 1998, 9, 1264-1269.	3.0	35
130	Lovastatin modulates in vivo and in vitro the plasminogen activator/plasmin system of rat proximal tubular cells. <i>Journal of the American Society of Nephrology: JASN</i> , 1998, 9, 1377-1388.	3.0	59
131	Modulation by Angiotensin II of Endothelial Cell Control of DNA Synthesis in Human Mesangial Cells. <i>Nephron</i> , 1997, 75, 303-309.	0.6	7
132	Interest and limits of in vitro studies in renal vascular endocrinology. <i>Cell Biology and Toxicology</i> , 1996, 12, 271-274.	2.4	1